Simone Botti

Simone Botti is a director at Precirix and was previously with Cardior Pharmaceuticals, Anavo Therapeutics BV, and INKEF Capital. From June 2016 to September 2020, they were the CEO of Metabomed Ltd., a drug discovery company in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. Prior to that, they served as a board member for IATI - Israeli Advanced Technology Industries from July 2012 to July 2015.

Simone Botti received their Ph.D. in Chemistry from the Weizmann Institute of Science and their Laurea in Chemistry from Sapienza Università di Roma.